A Multiomics Study Based on the Dynamic Evolution of Endometrial Carcinogenesis

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06007300

Enrollment

300

Registered

2023-08-23

Start date

2023-08-31

Completion date

2026-06-30

Last updated

2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiomics Analysis, the Dynamic Evolution of Endometrial Carcinogenesis

Keywords

Dynamic Evolution, Genomics, Transcriptome, Proteomics, Metabolomics

Brief summary

The goal of this observational study is to draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium, 100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial cancer; and then to explore the underlying molecular mechanism, and establish the database system for the dynamic evolution of endometrial carcinogenesis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pathological diagnosis: normal endometrium, atypical hyperplasia endometrium, or endometrial cancer; * Obtain pathological results after undergoing hysteroscopic surgery or hysterectomy; * The patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements; * Sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests.

Exclusion criteria

* Patients with malignant tumors in other parts of the body; * Suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders; * Poor compliance and inability to cooperate and describe treatment responders.

Design outcomes

Primary

Measure	Time frame
The mutant genes of participants and their expression as assessed by gene sequencing, RNA sequencing and mass spectrometry analysis	August 2023 to June 2026
Differences in the expression of these mutant genes among the three groups of participants as assessed by SAS® 9.4	January 2026 to June 2026

Outcome results